SubQ vs IM peptide injections: what the science actually shows

What's this video probably claiming?

Based on the caption and hashtag set, @susanpeps is walking beginners through the basics of subcutaneous versus intramuscular injection technique for peptides. The caption explicitly states that subQ targets the fat layer beneath the skin, while IM goes deeper into muscle tissue. The creator appears to claim that most peptides work adequately with subQ administration, and that checking product-specific guidance matters. The hashtags reference GHK-Cu, NAD, and what appear to be peptide vendor brands, suggesting the video is probably framed around a starter kit of commonly used research or compounded peptides. The audience skews toward fitness and biohacking communities with little clinical background, which makes the framing of injection route as a performance variable, not just a safety variable, worth examining carefully.

What does the science actually show?

On the basic anatomy: the creator is correct. SubQ injections deposit material into the hypodermis, typically 4 to 8 millimeters deep depending on site and body composition, while IM injections target skeletal muscle, usually 25 to 38 millimeters deep at sites like the deltoid or vastus lateralis. For most peptides discussed in fitness contexts, subQ is pharmacokinetically appropriate. A 2015 pharmacokinetics review by Benet et al. in the AAPS Journal confirmed that subcutaneous bioavailability for short peptides under 5 kDa is generally 70 to 90 percent, with absorption mediated through capillary uptake and lymphatic drainage. For peptides like ipamorelin and CJC-1295, subQ is the standard route used in the clinical trial literature, including Raun et al. (1998, European Journal of Endocrinology), which used subQ dosing for GHRP compounds. IM is not inherently better for most of these molecules and introduces unnecessary complication and injury risk for self-administering users.

Where does the social media noise diverge from clinical reality?

Here is where the peptide TikTok ecosystem consistently goes wrong. The implicit framing, visible across this hashtag cluster, is that injection route is a performance optimization variable. It is not, for most of these compounds. Choosing subQ over IM for ipamorelin does not meaningfully change peak GH secretion in the published data. A more serious problem is that videos like this normalize self-injection of compounds that have not completed Phase 3 clinical trials in humans. BPC-157, tagged adjacent in this creator category, has zero published human clinical trial data as of mid-2024. GHK-Cu, also tagged, has interesting wound-healing data in vitro and in animal models (Pickart and Margolina, 2018, Frontiers in Aging Neuroscience), but translating that to "inject this subQ for results" is a leap the peer-reviewed literature does not support. The vendor hashtags here, including one that appears to be a direct supplier tag, are a yellow flag for regulatory and sourcing transparency.

What should you actually know?

Injection technique matters, and the creator is right to say so, but the framing of subQ versus IM as a beginner tip glosses over more pressing issues. Sterility protocol, needle gauge selection, site rotation, and reconstitution accuracy are more consequential for safety than which layer you target. A 2020 analysis in the Journal of Clinical Pharmacology (Rissler et al.) found that improper reconstitution of lyophilized peptides is one of the leading causes of dosing error in non-clinical settings. Beyond technique, the regulatory status of these compounds is the elephant in the room. Many peptides circulating in the fitness market are sourced from unregulated suppliers, and purity testing data is rarely available to end users. Anyone considering peptide therapy should be doing so under physician supervision on a regulated platform, not from a TikTok injection tutorial. The caption cuts off mid-sentence, which itself is a signal that the guidance may be incomplete.